Illumina P/E
What is the P/E of Illumina?
The P/E of Illumina, Inc. is N/A
What is the definition of P/E?
Price to earnings ratio is the ratio of a company’s stock price to the company’s earnings per share calculated over trailing twelve months.
= previous day’s close / ttm EPS
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E of companies in the Miscellaneous sector on LSE compared to Illumina
What does Illumina do?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Companies with p/e similar to Illumina
- Enviro Technologie has P/E of N/A
- Arcimoto has P/E of N/A
- Tata Sponge Iron has P/E of N/A
- Sathavahana Ispat has P/E of N/A
- Crossword Cybersecurity Plc has P/E of N/A
- Urban Exposure Plc has P/E of N/A
- Illumina has P/E of N/A
- Revolution Lighting Technologies has P/E of N/A
- Vroom has P/E of N/A
- Orphazyme A/S has P/E of N/A
- Govind Rubber has P/E of N/A
- Rdi Reit P.L.C has P/E of N/A
- Acorn Income Fund has P/E of N/A